Epidemiology of chronic kidney disease: an update 2022.
Kidney international supplements · 2022 · 2,102 citations · Csaba Kovesdy
Development and Validation of the American Heart Association's PREVENT Equations.
Circulation · 2024 · 976 citations · Csaba Kovesdy
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
Journal of hepatology · 2022 · 1,506 citations · Ahmed Kaseb
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
The New England journal of medicine · 2022 · 1,350 citations · Javier Munoz
The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice.
Pregnancy hypertension · 2022 · 850 citations · Subbian Karumanchi
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
Lancet (London, England) · 2023 · 662 citations · Ahmed Kaseb
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Nature · 2021 · 1,101 citations · Ahmed Kaseb
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Lancet (London, England) · 2023 · 469 citations · Ahmed Kaseb